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Do We Have Enough Information?
Tom Nolis and Rodney J. Scott
Abstract
Genomics medicine and molecular genetics are experiencing a surge of interest
as well as a push for a more prominent role in mainstream medicine. This, coupled
with the advancement of next-generation sequencing, along with a national, if not
global, steering of funding to support the advancement and development of genet-
ics is suggesting that we are entering a new age of medicine. As this push begins to
gain some momentum, the impact of genomics medicine on clinical utility and the
influence of supporting data on genes that make their way from research to diag-
nostic medicine are worth reviewing.
Keywords: genetics, genomics, utility, cancer, BRCA1, BRCA2, PALB2, population,
family, epidemiology, multigene, panels
1. Introduction
One of the most fundamental clinical validity and clinical utility questions cur-
rently at the forefront of molecular genetic testing is as important today as it was
nearly 30 years ago, “is the genetic variation detectable in the genes of interest
actually associated with a clear and quantifiable risk for disease?” or in other words,
“are the variants that we are finding in these genes relevant for the disease of
interest?”
The question above is a very important one, and to be able to answer, it we must
take a step back and explore clinical utility and epidemiology in genetics more
thoroughly. The answer to this question requires an inevitable focus on cancer
genetics as breast and ovarian cancer are excellent examples of both past and
present accomplishments in genomics medicine. These disease entities are topical
and have enough data to appropriately highlight the genetic journey previously
taken into genomics medicine, and they are also able to shed light on how new
genetic players are entering the diagnostic scene (e.g., PALB2).
Finally, the following text will briefly compare and contrast the significant
influence of family-based and population studies on genetic data. This chapter will
close on a more general note by reviewing the current cancer assessment guidelines
and how these reflect the current clinical utility of genomics medicine.
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1.1 Key points
• Clinical utility in genetics is largely a continual revamp of the ACCE
framework.
• Genetic epidemiology has followed a natural flow paralleling the advancement
of technology and detection.
• Family-based studies and population data are still at the forefront of both
research genetics and diagnostic genomics.
• BRCA1 and BRCA2 are excellent models for useful genetics input.
◦ This has led to a complete change in the identification and treatment
of a very tangible cancer entity.
• Less penetrant genes in breast and ovarian cancer, such as PALB2, along with
multigene panels have their place in genomics medicine, but, generally, quality
supportive data are lacking.
2. Clinical utility in genetic testing
Clinical utility is a broad concept and one that is deeply fundamental in the
world of medicine. At its most basic level, it is the essence of what propels medical
advancement. It answers the question of “what should I do next?” when this ques-
tion is asked by physicians, but it can also be a much larger almost all encompassing
concept; as if to ask, “what is worth doing next?” in any field of medicine. Clinical
utility, by many sources, can be simply defined as “the balance of benefits to risks”
or more broadly refer to any use of test results to inform clinical decision-making
[1]. A genetic test can be defined as a “test that involves the analysis of chromo-
somes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), genes, or gene prod-
ucts (e.g., enzymes and other proteins) to detect heritable or somatic variations
related to disease or health. Whether a laboratory method is considered a genetic
test also depends on the intended use, claim or purpose of a test” [2].
In some fields, such as in colorectal surgery, it is easy to determine clinical
utility: if the patient’s morbidity or mortality is improved by removing a tumor,
then you remove it; otherwise you do not. In the realm of genetic testing, the
concept of clinical utility can be difficult to precisely define—or even quantify.
Indeed, this was reinforced when experts in evidence-based medicine and genetics
for the Centers for Disease Control and Prevention (CDC) in 2005 failed to come to
a consensus on the term “clinical utility” despite initially claiming to be confident in
its meaning beforehand [1]. As a consequence, the term had to be elaborated on by
the Analytic validity, Clinical validity, Clinical utility, and Ethical, legal and social
implications (ACCE) project that was carried out by the Foundation for Blood
Research with support from the CDC [1]. In screening or in diagnostic testing,
clinical utility broadly refers to the ability of a test to prevent or ameliorate adverse
health outcomes such as mortality, morbidity, or disability through the adoption of
efficacious treatments conditioned on test results (Figure 1) [1]. The perceived
value of genotypic information, at this point in time, includes a more thorough
understanding of a patient’s diagnosis, prognosis, risk, and disease or treatment
susceptibility; the caveat is that this knowledge may not influence clinical manage-
ment at all. Clinical utility in the ACCE framework was expanded to include
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contextual or implementation issues (e.g., availability of resources) and that clinical
utility can also include psychological benefits.
2.1 Evaluating genetic tests
Evaluating genetic tests is often methodologically difficult largely due to small
patient populations and the resulting dearth of high-quality studies. Adapted from
Morrison et al. 2012, the following subsections are generally agreed upon as com-
mon characteristics for reviewing genetic tests [3, 4].
2.1.1 Overview of disease and underlying genetics
• Information on the disease prevalence, treatments, and outcomes of the disease
as well as overall cost
• Description of the genetic causes, including inheritance patterns
• Classifying the mutational spectrum, along with the prevalence and penetrance
• Determination if there is any “gold standard” tests to compare to
2.1.2 Target population and intended use
• Prevalence for target population involves age, ethnicity, and eligibility for
testing
Figure 1.
Clinical utility in genetics. The clinical utility in screening tests is to provide preventative care and to improve
primary end points such as overall morbidity; in a diagnostic setting, the value of genetic testing lies in the
balance of benefits to risks in more psychological domains.
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• Purpose of the test: is it diagnostic, for treatment, prognosis, management,
carrier testing, prenatal testing, or other?
2.1.3 Laboratory information
• Validation details
◦ Test new or already in use?
▪ If already in use:
• Number and rate of positive and negative mutations
• Turn-around-time for results
• Similar tests available
• Current testing activity and expected with appropriate funding
figures
• Whether there are other laboratories that could offer the test
• Infrastructure requirements
• Quality assurance, maintenance, and improvement programs—both internally
and externally
2.1.4 Economic considerations
• Cost estimates for the test including equipment, personnel, and consumables/
reagents
• Costs of disease burden with or without treatment
• Costs saved by employing test
2.1.5 Analytic validity
• Precision, reliability, accuracy, sensitivity, and specificity of the genetic test,
and how these compare with other employed screening and diagnostic tests
2.1.6 Clinical validity
• Specificity and sensitivity, positive predictive value, negative predictive value,
likelihood ratios, and how these compare with other employed screening and
diagnostic tests
2.1.7 Clinical utility
• Benefits and risks of the test
• Treatment of the patient
4
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• Patient’s health outcome
• Effect on patient and patient’s family members
• Alternative diagnostic tests compare and contrast to genetic testing
2.1.8 Ethical, legal, and social
• Details on ethical, legal, and societal issues include support and follow-up
2.2 ACCE model and beyond
The CDC furthered the ACCE framework by establishing the Evaluation of
Genomic Applications in Practice and Prevention (EGAPP) Initiative. The EGAPP
supports the development and implementation of an evidence-based process for
evaluating genetic tests and other genomic applications for clinical and public health
practice. An independent, nonfederal EGAPPWorking Group (EWG), consisting of
a multidisciplinary expert panel selects topics of interest, reviews evidence, and
recommends courses of action [2]. Key objectives of the EWG are to develop an
openly accountable process, reduce conflicts of interest, and provide a connection
between well-established evidence and the EWG recommendations [2, 5].
The ACCE model has stood the test of time and has proven to be a basis for the
technical appraisal of genetic tests across the globe (Figure 2). The UK Genetic
Testing Network and the Andalusian Agency for Health Technology Assessment
expanded the ACCE model to guide the introduction of new genetic tests into their
Figure 2.
Genetic testing appraisal frameworks. Testing appraisal frameworks around the globe have largely stemmed
from the analytic validity, clinical validity, clinical utility, and ethical, legal and social implications (ACCE)
framework announced in 2000. EGAPP, evaluation of genomic applications in practice and prevention; ECRI,
Emergency Care Research Institute; NHS UKGTN, National Health Service UK Genetic Testing Network;
CAT, companion test assessment; GFH, German Society of Human Genetics.
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public health system, creating the 2004 NHS UKGTN Gene Dossier and the 2006
Andalusian Framework. In 2007, the ACCE model was again modified by adding
health quality measures to the evaluation process. The process was made more
streamlined, shortening the systematic review process for emerging genetic tests. In
2010, the ACCE model was adapted to particular types of genetic testing through
the Complex Disease Framework and the ACHDNC Newborn Screening Frame-
work of the Advisory Committee on Heritable Disorders in Newborns and Children.
The ACCE model also spawned two European frameworks: the 2008 GFH Indica-
tion Criteria of the German Society of Human Genetics and the 2010 Clinical Utility
Gene Card of EuroGentest. The 2015 Companion test Assessment Tool (CAT) build
upon the ACCE model to determine which tests needed further evaluation. In 2011,
the ECRI Institute utilized the EGAPP process to develop a set of analytical frame-
works for various testing scenarios and other stakeholder aspects. Lastly, the
EuroGentest inspired the 2017 Australian Clinical Utility Card [5].
We cannot ignore the influence of the stakeholders who will invariably have
wildly different opinions as to which outcomes are considered relevant. Thus, the
types of outcomes that must be considered in evaluating the utility of a genetic test
will also depend on the purpose of the test and the congregation of those who make
the final decision. For example, a state-funded public health program will likely
focus on the overall impact on morbidity and mortality versus privately funded
sectors concentrating on the greater net profit. Coverage decisions by third-party
payers may be based in large part on perceptions that test results are useful for
timely or accurate diagnoses and clinical management. For a test that is offered to
families in a clinical setting on a voluntary basis, the value of information for
making career, residential, and reproductive decisions take on greater relevance.
Before a genetic test can be accepted into clinical practice, data must be collected
to demonstrate the benefits and risks that accumulate from both positive and
negative results [1]. Referring back to the colorectal surgery example above, the
term “clinical utility” fits in very well; however, when applied to genetics or geno-
mics medicine, the term may be too limited. The clinical end points are extremely
important, but the utility or actionable context must remain broad in genetics to
embody an overall net benefit. Genetic testing is particularly useful in the psycho-
social, ethical, legal, and social (ELS) realms as well as in many diagnostic cases
(Figure 1). By including clinical and ELS together in the concept, improvements in
health outcomes such as enhancements in morbidity, mortality, and in disability
become strong primary end points when assessing the utility of genetic testing.
3. Genetic epidemiology: population and family-based studies
The process of genetic epidemiology has flowed sequentially from observing
phenotypic differences between populations to demonstrating that diseases can run
in families, to examining feasible genetic susceptibility models, to tracking co-
segregating genetic markers with disease in families, to narrowing the region of
candidate genes, to association analyses with candidate genes, to cloning and muta-
tion identification, to functional and structural characterization of a gene, and,
ultimately, to extending the phenotype characterization even further based on the
genotype identified (Figure 3) [6].
Population and family-based studies are at the heart of genetic epidemiology.
Population-based association studies are generally regarded as more statistically
powerful than family-based studies, as they tend to have more subjects and are
overall easier to execute [6]. Family-based designs are influential methods that use
the proband as well as their relatives to assess the genetic and molecular
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epidemiology of disease (Figure 4). The various types of studies available include
familial aggregation, twins, segregation, linkage, and association.
Linkage and association studies directly evaluate genetic markers and require
the collection of DNA from the study subjects—as opposed to twin studies,
segregation studies, and familial aggregations studies. Family-based studies have
been the long-standing primary approach to detect disease-causing genes.
Segregation and linkage studies are highly valuable methods for assisting in
Figure 3.
Genetic epidemiological historical progression.
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cloning highly penetrant rare disease-causing genes. Family-based association
studies strengths lie in their ability to control for confounding bias due to popula-
tion stratification—albeit they do so at a loss of power [1, 5, 6].
Population stratification is when contrived associations can be detected if cases
and controls come from different source populations that have systematic differ-
ences in ancestral allele frequencies. A great advantage of employing family-based
study designs is that population stratification can be circumvented. By studying
parents and their offspring/siblings, cases and controls within each family are
virtually guaranteed to arise from the same sample source or population. Due to the
increasing efficacy of identification of association with disease, the importance of
family-based studies has seemingly subsided; however, it is worth pressing that
family-based studies are arguably more important than they have ever been as they
are still the only way to truly link a causative variant to disease [1, 5, 6].
Family-based studies can help determine whether a disease or trait is genetically
influential by studying familial aggregation. Results can be furthered with a segre-
gation analysis to identify the mode of inheritance. The results from the segregation
analysis can add power to a linkage analysis, which searches across the entire
genome in an attempt to locate regions containing causal genes [1, 5, 6].
Segregation analysis is a method of establishing the genetic inheritance of dis-
ease and is performed exclusively with family data. This approach assists in
Figure 4.
A closer look at family-based and population studies.
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determining if a disease segregates with a variant in a single gene; in addition to
this, the mode of inheritance can also be ascertained. Very large pedigrees and
families with a plethora of affected individuals are exceptionally informative for
identifying specific genes [1, 5, 6].
Once a family is collected, and studied, in a segregation analysis, that family is
generally made available for further analyses (e.g., linkage). Linkage occurs when
two loci/alleles on the same chromosome are inherited together. Since recombination
during meiosis can occur virtually anywhere in the genome it stands to reason
that the closer two loci are to each other the less likely they will be separated after
a recombining event (i.e., the more likely they are to stay together after recombina-
tion), that is, it says they are “linked.” Linkage analyses utilize this phenomenon
by investigating co-segregating genetic markers along with a disease trait seen within
the family (or families)—the trait can be either qualitative or quantitative. If the
markers and traits are observed to co-segregate within families, it can be logically
inferred that the disease-causing variants are within close proximity to the markers
[1, 5, 6].
This point reveals that linkage is “intrafamilial,” whereby the co-segregating
marker allele may very well be different in different families. Families are generally
recruited into linkage studies on the basis of having at least one identified affected
individual, and the families are either quite large or have affected siblings. Gener-
ally, the markers are spaced evenly over the entire genome, and linkage can be
performed by utilizing these markers.
4. Breast and ovarian cancer: the journey of finding BRCA1 and BRCA2
Establishing penetrance is an arduous undertaking even for some of the most
well-studied genes (e.g., with BRCA1 and BRCA2) simply because no two genetic
studies have yielded the same findings. Many of the data and results discrepancies
can be linked to differences in the populations studied and to the methodologies
employed. It is vanishingly rare, if not impossible, for these studies to have similar
methodologies to allow for perfect reproduction of results. The range of penetrance
found for the BRCA variants and genes has guided the clinical recommendations for
breast and ovarian cancer surveillance and prevention and has provided a sort of
genetic “gold standard” by which all other genes are now compared and contrasted
against [7, 8].
A strong family history of breast cancer is associated with an early age of onset,
the addition of ovarian cancer, bilateral tumors, and a rarely affected male. BRCA1
(and similarly for BRCA2) has been identified through the study of women who
have presented with a strong family history of breast and ovarian cancer (Figure 5).
In 1988, more than 1500 families with multiple cases of breast and ovarian cancer
were studied; the data generated was subjected to a segregation analysis. The results
illuminated that roughly 5% of cases, particularly those with early-onset disease,
could be heritable in a Mendelian fashion. Selected families, those with near-
Mendelian pedigree patterns, were aggregated for linkage analysis. A major suscep-
tibility locus, BRCA1 (OMIM 113705), was mapped to 17q21 in 1990. 17q-linked
families that were above 45 years of age at diagnosis were given negative LOD
scores.
In 1994, a linkage analysis performed on 15 large families with breast cancer that
were also determined to not be linked to 17q helped identify the BRCA2 locus
located on 13q12 (OMIM 600185). Later that year BRCA1 was cloned, and in 1995
BRCA2 was cloned. BRCA1 variants accounted for a very large proportion of
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families with both breast and ovarian cancers, while male breast cancer was pre-
dominately observed in BRCA2 variant families [9].
BRCA1 and BRCA2 were identified by focusing on a small number of specific
families. Other candidate genes were established from focused studies.
• In 2004, the variant c.1100de1C in the CHEK2 gene was observed in 201 cases
(1.9%) and 64 controls (0.7%) in 10,860 breast cancer cases and 9065 controls
from 10 case-control studies in 5 countries (estimated odds ratio (OR) 2.34;
95% CI 1.72–3.20; P = 0.0000001) [10].
• In 2006, the ATM gene was screened in individuals from specific families, and
12 mutations were found in affected individuals and in 2 controls (P = 0.0047)
from 443 familial breast cancer pedigrees and 521 controls (estimated relative
risk of 2.37 (95% CI 1.51–3.78, P = 0.0003) [11].
Figure 5.
The progression of discovering the BRCA1 gene.
10
Modern Medical Genetics and Genomics
• BRIP1 was initially described as a breast cancer predisposition gene in 2006.
The analysis of 1212 women with familial breast cancer along with 2081
controls yielded mutations in 9 cases and in 2 controls (estimated relative risk
of 2.0; 95% CI = 1.2–3.2; P = 0.012) [12].
• PALB2 mutations were found in 10 cases of 923 individuals with familial
breast cancer, and no mutations were found in 1084 controls (P = 0.0004)
(estimated odd ratio of 2.3; 95% CI = 1.4–3.9; P = 0.0025) [13].
These factors are the most relevant in families where the disease and the
variant are actually segregating together, but at a population level, their overall
implication is surprisingly small. For instance, CHEK2:c.1100de1C, at a population
level, is seen in only 1.9% of cases [14].
5. Less penetrant genes: PALB2, BRIP1, and RECQL
Traditionally, epidemiological studies tend to emphasize the inclination that the
greatest benefits to the population are found in interventions that decrease risk
factors for the bulk of the population, not in targeting a small number of individuals
at the extreme ends of the risk spectrum. As we can see from the sample multigene
panel for hereditary breast cancer the genes selected for testing range from quite
influential (e.g., BRCA1 and BRCA2) to marginally influential (e.g., STK11)
(Table 1). However, it is quite interesting to explore the data for lower-risk genes
such as PALB2 and BRIP1 and also for genes that are suspected of having involve-
ment in breast or ovarian cancer, but the data is not quite yet congruent with the
theory (e.g., RECQL).
Less penetrant genetic loci are mainly represented by the single-nucleotide
polymorphisms (SNPs) or by the variants of uncertain significance discovered
through genome-wide association studies. Variants associated with a minor
increased risk, unlike high-risk mutations, can only account for a small portion of
cancers seen in family histories of carriers. Thus, the cumulative risk for carriers
with a positive family history will largely depend on the risk levels attributed to
both their family history for that cancer and the risk induced by the variant itself.
For example, if a carrier of a variant associated with an increased odds ratio of
cancer also has a family history sufficient to quadruple her risk, her cumulative risk
will be about that of a woman with a 4 x OR increased risk [7].
Mutations in ATM, PALB2, and CHEK2:c.1100delC, in conjunction with a
strong family history, are very likely to be associated with a high absolute risk
of breast cancer [17]. It is important to note that the family history creates a
context whereby it changes the penetrance of these mutations. This interpreta-
tion is clinically important and would justify testing for these mutations in
multi-case breast cancer families such as those seen by typical cancer family
genetics services.
Genetic risk factors, which are familial by their very definition, will be more
frequent in women with positive family histories involving multiple breast cancers
through their direct association with breast cancer as a disease entity and with their
direct association with the familial aspect of breast cancer. This can be illustrated in
a simple example where we consider a rare mutation whose presence doubles the
risk of breast cancer relative to the general population: it will be roughly four times
more common in women who are affected and who have an affected first-degree
relative, which will square the ratio [17].
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5.1 PALB2
The Finnish founder mutation was found in 0.9% (18 of 1918) of cases without
selecting for or emphasizing family history. Likewise, a French-Canadian founder
mutation was found in 0.6% (2 of 356) of cases also without selecting for or
emphasizing family history selected. The numbers of the PALB2 founder mutation
carriers were too small to make precise risk inferences, but modified segregation
analyses of data from the families of case-carriers were used to estimate risk for
carrier families, which has demonstrated the importance of these founder muta-
tions in the risk of developing breast cancer [13, 14, 18, 19].
Blanco et al. found that the frequency of PALB2 mutations was 1.5% after
investigating the incidence of mutations in PALB2 patients with breast cancer that
were also negative for any variants in BRCA1 and BRCA2 +/ a family history of
pancreatic cancer; previous studies had the mutation rate for similar cohorts range
from 0 to 4.8%. Dansonka-Mieszkowska et al. conducted similar research among
Polish women; their study showed a minor but significant PALB2 mutation pres-
ence at 0.6% [13, 14, 18, 19].
Sample multigene hereditary breast cancer panel
Gene Notes
ATM c.7271 T > G —
other ATM
mutations
Lack of data regarding penetrance and surveillance except for c.7171 T > G
mutation. If mutation has been identified, a careful assessment of residual risk for





CDH1 Increased risk of lobular breast cancer. Gastric cancer risk is unknown when
mutations are identified in absence of a positive family history of gastric cancer
CHEK2
c.1100delC
Mutations are rare, but high penetrance in some families
other CHEK2
mutations
Lack of penetrance data except for in specific mutations
NBN —
NF1 Can identify mutation carriers by clinical phenotype and then perform gene
specific test




PTEN Can usually be identified by clinical phenotype
RAD50 —
STK11 Can usually be identified by clinical phenotype. Low penetrance in breast cancer
TP53 Breast cancer risk management inferred from other genes. High penetrance for
breast cancer, but mutations are rare
Adapted from: Invitae and eviQ [15, 16].
Table 1.
Sample multigene panel offered for hereditary breast cancer.
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Likewise, Bogdanov et al. conducted a study on the occurrence of PALB2 muta-
tions among Russian and German women and reported a mutation rate of 2%. In
2014, Antoniou et al. tested 362 women from 154 families and found that the risk of
breast cancer in women 40 years of age or younger with PALB2 mutation was 9x
greater, 8x greater in patients aged 40–60 years, and 5x greater in patients
60 years and older when compared to the general population. The absolute risk of
breast cancer in women with PALB2mutations under 70 years of age ranges from
33 to 58% for women without and with a positive family history of breast cancer,
respectively. Interestingly, Hartley et al. conducted a study that confirmed that as
the number of cases of breast cancer in a family increases, the likelihood of PALB2
mutations increases as well. Women with 3+ positive cases of familial breast cancer
have a 2.6% greater likelihood of having a PALB2 mutation than those without
multiple cases [13, 14, 18, 19].
Southley et al. studied Australian women to determine the occurrence rate and
penetrance of PALB2 mutations. The study found that the women with breast
cancer and a positive family history of having PALB2 mutations had PALB2 muta-
tions present in 1% of patients. The study identified that the women with breast
cancer and no family history of PALB2 mutations had PALB2mutations present in
only 0.4% of patients. There were no PALB2mutations detected in the control/
healthy population of women. Heikkinen et al. studied southern Finnish women
and found PALB2 mutations in 2% of patients with a positive familial history of
breast cancer and also in 0.6% of women with a sporadic breast cancer presentation
[13, 14, 18, 19].
In 2016, a seminal paper by Thompson et al. examined 2000 predominantly
breast cancer-affected women with a strong family history that were also BRCA1
and BRCA2 variant-negative and compared them to 1997 controls. They observed
that a significant proportion of mutations were only in PALB2 (26 cases vs. 4
controls) and in TP53 (5 cases vs. none in controls), whereas no mutations were
identified in STK11 [14]. PALB2 is a great example of how penetrance estimates can
depend on the population, family history, and age at onset as well as other consid-
erations [17].
5.2 BRIP1
BRIP1 was initially described as a breast cancer predisposition gene in 2006.
The analysis of 1212 women with familial breast cancer along with 2081 controls
yielded mutations in 9 cases and in 2 controls (estimated relative risk of 2.0; 95%
CI = 1.2–3.2; P = 0.012). However, recently BRIP1’s association with breast cancer
has grown suspect, while its association with ovarian cancer has risen sharply.
BRIP1 mutations confer a high ovarian risk in familial index patients (OR = 20.97,
95% CI = 12.02–36.57; P < 0.0001) and in the subgroup of patients with late onset
ovarian cancer (OR = 29.91, 95% CI = 14.99–59.66; P < 0.0001) [12].
5.3 RECQL
In a screen of 144 Polish and 51 French-Canadian women with early-onset
familial breast cancer, 2.6% possessed truncating mutations in RECQL. Validation
studies that reviewed the RECQL variant c.1667_1667C3delAGTA in over 13,000
breast cancer patients with 4702 Polish controls showed the RECQL mutation
appeared in 0.23% of cases and in 0.04% in controls. Likewise, the RECQL variant
c.634C > T (p. Arg215*) seen in the French-Canadian population was further
screened in 538 patients and 7136 newborn controls and was detected in 5 patients
and in one control—a nearly 50x increase in frequency in affected versus
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unaffected individuals. Studies of patients in northern China revealed a patho-
genic RECQL mutation in 2.0% of the 448 familial breast cancer patients com-
pared to the 0.06% seen in 1588 control subjects [20]. By whole exome sequencing
0 early-onset familial breast cancer patients without BRCA1/2 mutations and by
screening the RECQL gene in an additional 439 unrelated familial breast cancer
patients, 9 index cases were found to carry a pathogenic mutation in the RECQL
gene among the 448 BRCA-negative familial breast cancer patients. It was deter-
mined that the pathogenic mutation rate of the RECQL gene in familial breast
cancer in BRCA1-/BRCA2-negative breast cancer patients was 2.0%. Further to
these results, no loss of heterozygosity was found in the RECQLmutation carriers,
suggesting that RECQL-associated tumorigenesis is likely through classical
haploinsufficiency [21].
In 2018, Li et al. sequenced all the exons of RECQL and at least 10 bp of the
exon–intron flanking regions in 9112 subjects from Australia. The case subjects
were females diagnosed with breast or ovarian cancer from 4536 families with a
negative result after BRCA1 and BRCA2 mutation testing. The controls were 4576
women who were above 40 years of age and were cancer-free as of May 2016.
Thirteen loss-of-function mutations in the cases and 25 in the controls were
identified (0.29 versus 0.55%, odds ratio 0.52, 95% confidence interval 0.25–1.06,
P = 0.072 by two-tailed Fisher’s exact test) [22]. Missense variants observed
between cases and controls were not statistically significant (54 cases, 1.19%,
versus 37 controls, 0.81%; P = 0.073) [22]. It is generally accepted that a predis-
position gene is considered actionable only if the 90% confidence limit of the
estimated relative risk is greater than four [22]; therefore, RECQL, can be
excluded based on these findings.
5.4 Lack of data and the impact of finding a variant of unknown significance
Despite the intense and widespread shared enthusiasm to reduce the risk of
predictable cancers, the adoption of the more recent breast cancer predisposition
genes, such as PALB2, has been sluggish. This has been largely due to the com-
munal appreciation that following a variant of unknown significance result, the
complexity of interpretation may lead to a subsequent clinical utility hindrance.
An additional 3.9% of patients tested by multiple gene panels had pathogenic
mutations identified in other breast cancer predisposition genes, namely, in
PALB2, CHEK2, and ATM; however, many of these multigene panel tests also
identified many variants of uncertain significance, where the classification is
either uncertain or simply just not possible—and this information cannot safely be
utilized clinically [19].
Indeed, this consideration is shared in recent literature and has been extended
by Thompson et al. where the authors examined various genes that are common on
hereditary breast cancer panels. They observed that the frequency of mutations in
most breast cancer panel genes is quite low, or even, in most cases, similar to the
frequency of mutations observed in cancer-free population controls. They con-
cluded that panels have the potential to provide clinical misinformation and harm at
the individual level if the data is not interpreted with extreme caution [14]. This
lack of evidence for new genetic players is not limited to breast and ovarian cancer,
but it also plagues many other genetic diseases and also afflicts a great number of
other multigene panels [19].
Due to this lack of supportive data, international large-scale studies into the
genes included in these multigene panels are absolutely critical to increase the
utility of the information yielded and also to ensure that the new genetic informa-
tion presented is both safe and useful in a clinical setting.
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6. Conclusions
Keeping in-line with global regulation entities such as CAT, EGAPP, NHS
UKGTN, and the ACCE backbone discussed above, the recent initiative eviQ pro-
vides a variety of guidelines for cancer genetics investigations. EviQ is part of the
Cancer Institute NSW (New South Wales) and provides evidence-based informa-
tion to support health professionals in the delivery of cancer treatments available at
the time treatment decisions are being made. We can see from the eviQ’s general
practitioner referral guidelines for cancer genetics assessment that generally, even
in oncology, genetics plays a large part in the diagnostics of disease [23]. We can
also note that there must be a strong clinical suspicion of the diagnosis involving a
genetic element (e.g., quite young, strong family history, hailing from a region with
restricted gene flow, etc.) to warrant testing and for it to be useful.
The clinical utility of genetics is highly variable and dependent on the gene or
disorder involved, but genomics medicine appears to be very good at revealing a
diagnosis, and, at times, it can help explain why the phenotype is the way it is. In
oncology, genetic testing plays an integral role in disease management by influenc-
ing treatment options or by being a major inclusion component for clinical trials.
Where genetic testing is taking off and, perhaps, where its true potential lies is in its
ability to offer predictive and preventative medicine, particularly for families, as
opposed to adhering to a purely reactive approach that is typically employed in
mainstream medicine.
Genomics is by no means irrelevant; it is revealing much about human disease
and pathophysiology, but barring the current leaps and bounds observed in oncol-
ogy, genomics medicine is still in an informational gathering phase—albeit, it is
doing so at an alarming and unparalleled rate. It will take a great deal more data,
analysis, and time before it will be considered true mainstream medicine, but there
is no doubt that genomics is the future of medicine.
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